Key Takeaway
What is the average weight loss on semaglutide 2.4mg? Detailed breakdown of clinical trial results, real-world outcomes, and factors that influence how much weight you can expect to lose at the full maintenance dose.
The average weight loss on semaglutide 2.4mg is 14.9% of body weight[1] over 68 weeks, according to the landmark STEP 1 trial[1]. For a 230-pound person, that translates to roughly 34 pounds. Over one-third of participants lost 20% or more of their body weight, a result previously only achievable through bariatric surgery.
Clinical Trial Results Across the STEP Program
Semaglutide 2.4mg has been studied in one of the largest clinical trial programs ever conducted for a weight management medication. Each STEP trial examined a different patient population, providing a thorough picture of what to expect:
| Trial | Population | Average Weight Loss | Duration |
|---|---|---|---|
| STEP 1 | Adults with obesity, no diabetes | 14.9% | 68 weeks |
| STEP 2 | Adults with obesity + type 2 diabetes | 9.6% | 68 weeks |
| STEP 3 | Adults with obesity + intensive behavioral therapy | 16.0% | 68 weeks |
| STEP 5 | Adults with obesity, 2-year study | 15.2% | 104 weeks |
| STEP 8[5] | Head-to-head vs. liraglutide | 15.8% | 68 weeks |
Several patterns stand out. Patients without diabetes lose more weight than those with diabetes, likely because insulin and other diabetes medications promote fat storage. Adding intensive behavioral therapy (STEP 3) boosts results to 16%. And the two-year STEP 5 data confirms that weight loss is maintained over time.
What These Averages Look Like in Real Pounds
Percentages can be hard to visualize. Here is what 14.9% weight[1] loss looks like for patients at different starting weights: For a complete cost breakdown, see our compare semaglutide prices.
View data table
| Category | Mean Body Weight Loss (%) | Detail |
|---|---|---|
| Tirzepatide | 22 | ~22% body weight at 72 wks |
| Semaglutide | 15 | ~15% body weight at 68 wks |
| Liraglutide | 8 | ~8% body weight at 56 wks |
| Retatrutide | 24 | ~24% in Phase 2 trial |
| Starting Weight | Average Weight Lost (14.9%) | New Weight |
|---|---|---|
| 180 lbs | 27 lbs | 153 lbs |
| 200 lbs | 30 lbs | 170 lbs |
| 230 lbs | 34 lbs | 196 lbs |
| 260 lbs | 39 lbs | 221 lbs |
| 300 lbs | 45 lbs | 255 lbs |
| 350 lbs | 52 lbs | 298 lbs |
Remember that these are averages. Individual results range widely, from minimal weight loss in some patients to over 25% in top responders.
Responder Analysis: The Range of Outcomes
Looking beyond averages reveals how varied the results can be. In STEP 1, the responder analysis showed :
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →- 86% of patients lost at least 5% of body weight (vs. 32% placebo)
- 69% lost at least 10% (vs. 12% placebo)
- 50% lost at least 15% (vs. 5% placebo)
- 32% lost 20% or more (vs. 2% placebo)
This means roughly one in three patients achieves results comparable to gastric sleeve surgery. Even among the lower responders, the vast majority lose at least 5%, which is the threshold considered clinically meaningful for improving blood pressure, blood sugar, and cholesterol.
Factors That Influence Your Results
Several variables help explain why one patient might lose 25% and another might lose 8%:
- Diabetes status: Type 2 diabetes reduces average weight loss by roughly 5 percentage points. The STEP 2 diabetic cohort averaged 9.6% vs. 14.9% in the non-diabetic STEP 1 cohort.
- Concomitant medications: Insulin, sulfonylureas, beta-blockers, certain antidepressants (mirtazapine, paroxetine), and antipsychotics can promote weight gain or limit loss.
- Dietary engagement: Patients who combine semaglutide with structured dietary changes (protein-focused, reduced processed foods) tend to outperform those who rely on appetite suppression alone. STEP 3 demonstrated that intensive behavioral therapy added approximately 1 to 2 percentage points.
- Exercise: Combining aerobic and resistance exercise preserves muscle mass and increases total energy expenditure, both of which enhance weight loss results.
- Starting BMI: Patients with higher starting BMI tend to lose more total pounds but a similar percentage of body weight.
- Age: Older patients may lose weight more slowly due to lower metabolic rates and reduced physical activity capacity.
- Genetics: Variations in GLP-1 receptor sensitivity, gut hormone profiles, and metabolic efficiency create innate differences in drug response.
How Semaglutide 2.4mg Compares to Other Options
| Treatment | Average Weight Loss | Duration |
|---|---|---|
| Semaglutide 2.4mg (Wegovy) | 14.9% | 68 weeks |
| Tirzepatide 15mg (Zepbound) | 22.5% | 72 weeks |
| Liraglutide 3mg (Saxenda) | 6.4% | 68 weeks |
| Phentermine-topiramate (Qsymia) | 9.8% | 56 weeks |
| Gastric sleeve surgery | 25 to 30% | 12 to 18 months |
| Diet and exercise alone | 3 to 5% | Variable |
Semaglutide 2.4mg is the second most effective non-surgical weight loss treatment available, behind tirzepatide 15mg. It substantially outperforms all older pharmacologic options. semaglutide vs tirzepatide comparison
Medical References
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. [PubMed | ClinicalTrials.gov | DOI]
- Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984. [PubMed | ClinicalTrials.gov | DOI]
- Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3). JAMA. 2021;325(14):1403-1413. [PubMed | ClinicalTrials.gov | DOI]
- Garvey WT, Batterham RL, Bhatt DL, et al. Two-year effects of semaglutide in adults with overweight or obesity (STEP 5). Nat Med. 2022;28(10):2083-2091. [PubMed | ClinicalTrials.gov | DOI]
- Rubino DM, Greenway FL, Khalid U, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes (STEP 8). JAMA. 2023;327(2):138-150. [PubMed | ClinicalTrials.gov | DOI]
Frequently Asked Questions
- Is 14.9% weight[1] loss the most I can expect?
- No. That's the average. One-third of patients exceed 20% weight loss, and some patients in the STEP trials lost over 30%. Your individual result depends on the factors discussed above, especially dietary engagement and exercise habits.
- How does semaglutide 2.4mg weight loss compare in men vs. women?
- Clinical trial subgroup analyses show similar percentage weight loss between men and women on semaglutide. Men may lose more absolute pounds due to higher starting weights, but the relative effectiveness is comparable.
- What if I have already lost weight before starting semaglutide?
- Patients who have already lost some weight through diet and exercise can still benefit from semaglutide. The medication helps prevent regain and may produce additional loss. Your percentage loss will be calculated from your starting weight at the time you begin treatment.
- Does weight loss continue after 68 weeks at 2.4mg?
- The STEP 5 two-year study showed that weight loss at 104 weeks (15.2%) was slightly higher than at 68 weeks, suggesting a small amount of additional loss continues. But most of the weight loss occurs in the first 9 to 12 months.
- What happens to my weight loss if I drop to a lower dose?
- Stepping down from 2.4mg to 1.7mg may result in slightly less appetite suppression and some patients experience modest weight regain. But many patients maintain most of their weight loss at the lower dose. semaglutide 1.7mg weight loss average
Talk to a licensed provider
Start your free assessment. A licensed provider reviews every request before anything is prescribed, and not everyone qualifies.
Start the assessment →